A further limitation of the current study is that the transient nature of this murine pulmonary infection model requires the i.p. treatments of MEK1/2 inhibitor compounds to be provided immediately prior to infection, limiting the ability to better model a translational intervention where ATR-002 treatment could be provided subsequent to infection. This evidence concerns the gene MAP2K1 and infection.